

Running head: APOE, TAU, AND COGNITION

APOE interacts with tau PET to influence memory independently of amyloid PET

Alexandra J. Weigand¹, Kelsey R. Thomas^{2,3}, Katherine J. Bangen^{2,3}, Graham M.L. Eglit², Lisa Delano-Wood^{2,3}, Paul E. Gilbert⁴, Adam M. Brickman⁵, & Mark W. Bondi^{2,3}, for the Alzheimer's Disease Neuroimaging Initiative

¹San Diego State University/University of California, San Diego Joint Doctoral Program;

²Veterans Affairs San Diego Healthcare System; ³Department of Psychiatry, University of California, San Diego; ⁴Department of Psychology, San Diego State University; ⁵Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, College of Physicians and Surgeons, Columbia University

Address correspondence to:

Mark W. Bondi, Ph.D., ABPP-CN
VA San Diego Healthcare System (116B)
3350 La Jolla Village Drive
San Diego, CA 92161
Phone: (858) 646-2809
Email: mbondi@ucsd.edu

Manuscript word count: 2965

Number of tables and figures: 3 (1 table, 2 figures)

Number of references: 43

Abstract

Objective: Apolipoprotein E (APOE) interacts with AD pathology to promote disease progression. Studies of APOE risk primarily focus on amyloid, however, and little research has assessed its interaction with tau pathology independent of amyloid. The current study investigated the moderating effect of APOE genotype on independent associations of amyloid and tau PET with cognition.

Methods: Participants included 297 older adults without dementia from the Alzheimer's Disease Neuroimaging Initiative. Regression equations modeled associations between cognitive domains and (1) cortical A β PET levels adjusting for tau PET and (2) medial temporal lobe (MTL) tau PET levels adjusting for A β PET, including interactions with APOE ϵ 4 carrier status.

Results: Adjusting for tau PET, A β was not associated with cognition and did not interact with ϵ 4 status. In contrast, adjusting for A β PET, MTL tau PET was significantly associated with all cognitive domains. Further, there was a moderating effect of ϵ 4 status on MTL tau and memory with the strongest negative associations in ϵ 4 carriers and at high levels of tau. This interaction persisted even among only A β negative individuals.

Interpretation: APOE ϵ 4 genotype strengthens the negative association between MTL tau and memory independently of A β , although the converse is not observed, and this association may be particularly strong at high levels of tau. These findings suggest that APOE may interact with

tau independently of $A\beta$ and that elevated MTL tau confers negative cognitive consequences in $A\beta$ negative $\epsilon 4$ carriers.

Introduction

For the past 25 years, research on Alzheimer's disease (AD) has been driven by an amyloid-centric model of disease pathogenesis.¹ This model purports that AD is initiated by abnormal amyloid beta (A β) accumulation, later followed by tau-mediated neurofibrillary tangle formation, neurodegeneration, and downstream cognitive deficits.^{2,3} Accordingly, most research on apolipoprotein E ϵ 4 (APOE ϵ 4) allelic effects, as the strongest susceptibility gene for increased risk and accelerated onset of AD,^{4,5} has focused on its associations with A β . Research has demonstrated that APOE is involved in the oligomerization, aggregation, degradation, and clearance of A β ,^{6,7} and that ϵ 4 carriers have increased incidence of A β PET positivity as well as accelerated A β PET accumulation.^{8,9}

Recent findings, however, also point to tau phosphorylation as an early event in preclinical sporadic AD, possibly even preceding the involvement of A β .^{10,11,12} The presence of cerebral tau pathology in the absence of A β remains a controversial topic, with some suggesting that this is a normal age-related phenomenon when confined to the medial temporal lobe (MTL; see [13] for a review of primary age-related tauopathy, or 'PART') and others citing evidence that it represents an early stage on the AD continuum.¹⁴ A recently proposed AD diagnostic framework incorporating A β , tau, and neurodegeneration biomarkers (i.e., A/T/N) reinforces the primacy of A β over tau by labeling A β alone as "Alzheimer's pathologic change" whereas tau alone is labeled "non-AD pathologic change".^{3,15} Studies investigating tau independently of A β are needed to further our understanding of biomarker dynamics in preclinical AD.

Although animal studies implicate APOE in the formation of tau pathology independently of A β ,^{16,17} there is a paucity of analogous research investigating APOE-related effects on tau measured through cerebrospinal fluid or positron emission tomography (PET) independently of one's A β level. Specifically, studies investigating APOE, tau PET, and their interactive effects on cognition in A β negative individuals are notably lacking. Given this gap in the literature, we independently assessed associations between cognitive performance and (1) cortical A β PET controlling for MTL tau PET, as well as (2) MTL tau PET controlling for cortical A β PET, along with interactions with APOE ϵ 4 status. For any interaction between PET and ϵ 4 status, we also ran stratified follow-up analyses assessing these interactions separately among individuals with negativity and positivity for the other pathology (e.g., tau by APOE interaction on cognition in A β positive [A+] and negative [A-] individuals). We conducted these analyses with the hypothesis that presence of an APOE ϵ 4 allele would have a deleterious moderating effect on the association between tau and cognition independent of A β PET level and regardless of A β positivity status.

Methods

Participants

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of

MCI and early AD. This research was approved by the Institutional Review Boards of all participating sites, and written informed consent was obtained for all study participants. Participants without dementia (n = 212 with normal cognition; n = 89 with mild cognitive impairment [MCI]) from the ADNI were selected based on the availability of tau and A β PET data acquired within 12 months of each other, as well as APOE genotype data (n = 297).

PET processing

Processing methods for ADNI A β PET (^{18}F -AV-45, florbetapir) and tau PET (^{18}F -AV-1451, flortaucipir) have been previously described elsewhere (<http://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/>). Based on extant processing recommendations, regional standardized uptake values (SUVs) were intensity normalized using the whole cerebellum^{18,19} (A β PET) or inferior cerebellar gray^{20,21} (tau PET) to create SUV ratios (SUVRs). Tau PET data were partial volume corrected using the geometric transfer method.²² For A β PET, a cortical summary measure was created by averaging across FreeSurfer-derived frontal, cingulate, lateral parietal, and lateral temporal regions of interest to capture early vulnerable regions for A β deposition.¹⁸ For tau PET, a Braak stage I/II composite region was created by averaging across FreeSurfer-derived hippocampal and entorhinal regions of interest to recapitulate tau progression in early Braak stages.^{20,21}

Although previous work has determined positivity thresholds via differing methods,²³⁻²⁵ positivity thresholds in this study were derived using conditional inference decision tree regression with the `ctree()` function from the party package in R (<https://cran.r-project.org/>) in order to: (1) remain consistent with prior derivations of tau PET thresholds in ADNI;^{21,26} (2) maintain comparable methods in the derivation of optimal thresholds for both A β and tau; and

(3) independently derive thresholds for A β and tau, rather than determining thresholds for one based on discrimination of the other biomarker.^{23,25} Thresholds were determined using binary classification of individual SUVRs based on global cognitive function (i.e., Mini-Mental State Examination scores) and were taken at the lowest-level bifurcation in the tree, unless otherwise noted. A larger sample of individuals (n = 523) spanning all diagnostic categories (i.e., cognitively normal, MCI, dementia) with tau PET data and a subset with A β PET data were included for threshold derivation. A threshold of SUVR > 1.14 was determined for cortical A β positivity (A+/A-); although this threshold came from a higher-level bifurcation, it was selected in order to maintain consistency with other commonly used A β thresholds (e.g., >1.11).^{18,27} For tau PET, thresholds were first determined for higher Braak composite stages (i.e., >1.96 for stage V/VI and >1.51 for stage III/IV), with individuals surpassing the positivity threshold for higher stages iteratively removed during derivation of lower-stage thresholds, as described elsewhere.²⁶ Ultimately, a threshold of SUVR > 1.18 was determined for tau Braak I/II (i.e., MTL) positivity (T+/T-), largely consistent with a previously derived threshold using similar methods (>1.13).²¹

Cognitive testing

Participants underwent comprehensive neuropsychological testing including the measures from the following domains: attention/executive function (Trail Making Test Parts A and B, time to completion); language (confrontation naming [i.e., Boston Naming Test or Multilingual Naming Test] and animal fluency); and memory recall (Logical Memory Story A Immediate and Delayed Recall). All raw scores were converted to z-scores based on predicted values from regression equations adjusting for age, sex, and education derived within a robust

normal control group (i.e., cognitively normal throughout their duration in ADNI) based on the entire ADNI sample. Z-scores were then averaged within domains to create attention/executive, language and memory composite scores. MCI was diagnosed using actuarial neuropsychological criteria.^{28,29} Participants were diagnosed with MCI if they (1) had two impaired scores in one cognitive domain or (2) had one impaired score across all three cognitive domains.

APOE genotyping

All participants had APOE $\epsilon 4$ genotyping data available. $\epsilon 4$ carriers and non-carriers were determined based on presence of at least one $\epsilon 4$ allele. Of the 297 participants overall, 99 (33%) were categorized as $\epsilon 4$ carriers (heterozygotes $n = 82$; homozygotes $n = 17$) and 198 (67%) as non-carriers.

Statistical analyses

Cognitive domain z-scores were shifted to a positive scale and Box-Cox transformed to improve normality. Tau PET SUVRs were also Box-Cox transformed to improve normality. All figures depict untransformed values to facilitate interpretation. Chi-squared tests and t-tests assessed for differences in demographic variables, PET values, and cognitive composite scores between $\epsilon 4$ carriers and non-carriers. Regression equations predicted demographically-adjusted and Box-Cox transformed cognitive z-scores as a function of cortical A β PET SUVRs while controlling for MTL tau PET SUVRs (model 1) and MTL tau PET SUVRs while controlling for cortical A β PET SUVRs (model 2). Both models included linear and quadratic SUVR-of-interest main effects controlling for APOE $\epsilon 4$ status and, in separate models, interactions with APOE $\epsilon 4$ status. For any significant linear or quadratic interactions, follow-up analyses examined these

interactions stratified by PET positivity status (e.g., tau PET and $\epsilon 4$ interactions for separately for A- and A+ individuals). All analyses and figures were generated in R version 3.5.0 (<https://cran.r-project.org/>).

Results

Sample characteristics

Group differences between $\epsilon 4$ carriers and non-carriers are presented in Table 1. Participants' sex distribution and years of education did not differ between carriers and non-carriers, but $\epsilon 4$ carriers were younger. APOE $\epsilon 4$ carriers had a higher average cortical A β SUVR and a higher proportion of A β positive individuals relative to non-carriers. Further, $\epsilon 4$ carriers had a higher average MTL tau SUVR relative to non-carriers, although the proportion of tau positive individuals was similar between groups. APOE $\epsilon 4$ carriers and non-carriers did not differ in any cognitive domain.

APOE by A β interaction on cognition

In models adjusting for tau PET SUVR and $\epsilon 4$ status, there was no linear or quadratic main effect of A β on cognitive performance in any domain (all t s < |1.44|, p s > .15). Further, no moderating effect of $\epsilon 4$ status was observed for the linear and quadratic associations between cortical A β SUVRs and any cognitive domain (all t s < |1.24|, p s > .22) while controlling for MTL tau PET SUVR.

APOE by tau interaction on cognition

In models adjusting for cortical A β PET SUVR and $\epsilon 4$ status, there was a linear main effect of MTL tau for attention/executive performance (β = -.21, t = -3.46, p < .001) such that higher levels of tau were associated with poorer attention/executive performance. There was

also a quadratic main effect of MTL tau for language ($\beta = -.25$, $t = -3.46$, $p < .001$) and memory ($\beta = -1.09$, $t = -2.45$, $p < .001$) such that higher levels of tau were associated with worse performance and this negative association was disproportionately stronger at higher levels of tau. Further, a moderating effect of $\epsilon 4$ status was observed for the association between quadratic MTL tau SUVRs and memory performance ($\beta = .73$, $t = 3.54$, $p < .001$) such that $\epsilon 4$ carriers exhibited a disproportionately stronger negative association between tau and memory at higher levels of tau (see Figure 1). Notably, the moderating effect of $\epsilon 4$ status on quadratic MTL tau-memory associations was upheld even among individuals who had not yet reached Braak stage III/IV ($\beta = .49$, $t = 2.91$, $p = .004$). There were no moderating effects of $\epsilon 4$ status for the associations between linear or quadratic MTL tau and language or attention/executive performance (all t s $< |1.59|$, p s $> .11$).

Follow-up stratified analyses were conducted for the interaction between APOE $\epsilon 4$ status and MTL tau level on memory performance to examine the effects separately for A β negative (A-) and positive (A+) individuals. Among A+ individuals, a moderating effect of $\epsilon 4$ status on linear MTL tau and memory performance was observed ($\beta = 1.02$, $t = 2.17$, $p = .03$) such that higher levels of tau were more strongly associated with poor memory performance among $\epsilon 4$ carriers (see Figure 2A). However, unlike in the model with the full sample, no interaction was observed for the quadratic effect of MTL tau in this A+ group ($\beta = .07$, $t = .79$, $p = .43$). In contrast, among A- individuals, a moderating effect of $\epsilon 4$ status on quadratic MTL tau and memory performance was observed ($\beta = .20$, $t = 2.12$, $p = .03$) such that a negative association between tau and memory emerged only for higher levels of tau among $\epsilon 4$ carriers (see Figure 2B).

Discussion

Moderating effects of $\epsilon 4$ status on the association between AD PET biomarker levels and cognition were observed only for associations between tau PET and memory, such that higher levels of tau were associated with poorer memory performance only among $\epsilon 4$ carriers, and this effect was disproportionately strong at higher levels of tau. Notably, this interaction was observed independently of $A\beta$ PET level as measured on a continuous scale and among individuals who were $A\beta$ negative via a threshold method. Further, independently of $A\beta$ PET level and $\epsilon 4$ status, tau PET was negatively associated with both language and attention/executive performance. In contrast, when adjusting for tau PET level, no main effects of $A\beta$ PET or moderating effects of $\epsilon 4$ status on cognition were observed. These findings suggest that tau interacts with APOE $\epsilon 4$ independently of $A\beta$ to exert negative influences on cognition, warranting a primary role for tau within the preclinical AD framework.^{3,30}

As a consequence of the amyloid cascade model, the majority of research on AD over the past few decades has focused on the role of $A\beta$ in AD¹ or, at the very least, investigated other pathologic markers in the context of $A\beta$ positivity—but less so among those with $A\beta$ negativity. Although a more recent model of AD pathogenesis known as the A/T/N framework³¹ has expanded its purview and purports agnosticism to the temporal sequencing of mechanisms underlying AD pathogenesis, it still relegates tau in the absence of $A\beta$ to an alternative categorization of “non-AD pathologic change.” In contrast to these amyloid-centric models, there is accumulating evidence in support of a continuum hypothesis in which tau pathology accumulates in the brainstem and propagates to transentorhinal cortex independently of and prior to $A\beta$.^{11,32,33} Only cases with tau positivity in the absence of $A\beta$ and clinical dementia

would warrant “non-AD pathologic change,” but individuals in this pathologic category without dementia are considered on the Alzheimer’s continuum.¹⁴ Additionally, recent research consistently shows strong associations between tau PET and cognition that are not evident with A β PET.³⁴⁻³⁶ Our findings of a moderating effect of APOE ϵ 4 status on tau and memory associations independently of A β , which persists among A β negative individuals, build upon these prior studies to provide further support for the notion that tau has a role in AD nosology independent from A β .

The mechanisms by which APOE ϵ 4 exerts its deleterious effects are incompletely understood, although both A β -dependent and -independent avenues have been explored. In addition to its role in the aggregation and clearance of A β , APOE has been implicated in neuroinflammatory processes, cerebrovascular alterations, and synaptic plasticity,³⁷ but its direct and indirect effects on tau pathology remain unclear. Evidence suggests that misfolding and aggregation of tau may be directly influenced by APOE-relevant processes.¹⁷ Further, a mouse model of tauopathy expressing different APOE genotypes demonstrated that ϵ 4 knock-in mice had, in addition to higher tau levels, higher microglial reactivity and tumor necrosis factor alpha (TNF- α) secretion, indicating an ϵ 4-induced neuroinflammation independent of A β .¹⁶ Thus, our findings may reflect possible APOE-mediated inflammatory processes exacerbating tau-mediated neurodegeneration, resulting in the observed associations with cognition.

Given findings that APOE regulates clearance of A β pathology,^{38,39} it is reasonable to speculate that it may be involved in the clearance of tau pathology as well. Although pathologic tau aggregates intraneuronally to form large fibrillar structures known as tangles, smaller

soluble oligomers exist both intra- and extra-cellularly. These toxic oligomeric tau species form prior to tangles, spreading through neighboring cells in a transsynaptic process to seed the aggregation of intraneuronal tangles.⁴⁰ Soluble oligomeric tau species may exacerbate inflammatory processes⁴¹ as well as inhibit post-synaptic proteins, reduce gliotransmitter release, and impair long-term potentiation and memory.^{42,43} Reduced clearance of these tau oligomers in $\epsilon 4$ carriers may potentiate these negative effects, resulting in the observed strengthened associations between tau and memory performance among $\epsilon 4$ carriers.

When stratifying the tau-memory associations based on $A\beta$ positivity, differential patterns of $\epsilon 4$ moderation were observed. Among $A\beta$ negative individuals, $\epsilon 4$ carriers exhibited a quadratic effect such that a negative association between tau and memory emerged only at higher levels of tau. In contrast, among $A\beta$ positive individuals, a linear interaction was observed such that the negative association between all levels of tau and memory was stronger in $\epsilon 4$ carriers. It is conceivable that, in the context of high $A\beta$, tau is associated with poorer memory even at relatively lower tau levels because the combined effects of $A\beta$ and $\epsilon 4$ status on neuroinflammatory processes lower the threshold such that less tau is needed to initiate neurodegeneration and cognitive dysfunction. Instead, when $A\beta$ levels fall below the positivity threshold, a higher amount of tau pathology in combination with $\epsilon 4$ -associated processes may be needed to exert a negative effect on memory, explaining the observed quadratic effect among $A\beta$ negative individuals. Notably, the strongest negative effects of tau on memory emerged for both groups soon after the SUVR had surpassed the Braak I/II positivity threshold, indicating a potentially important threshold effect for tau regardless of $A\beta$ status. Further, given the quadratic nature of the interaction such that effects on memory were most prominent at

higher levels of MTL tau, analyses were rerun among only individuals negative for Braak stage III/IV; the $\epsilon 4$ interaction on quadratic MTL tau-memory associations was retained, suggesting that the strengthened effect for high MTL tau is not driven by individuals who have reached Braak stage III/IV.

The primary strength of this study was the investigation of the moderating effects of APOE $\epsilon 4$ on both A β and tau PET independently, resulting in the novel finding that the quadratic association between tau PET and memory was retained in $\epsilon 4$ carriers even among A β negative individuals. Further, assessing multiple cognitive domains broadened the scope of investigation beyond memory to demonstrate robust main effects of MTL tau on language and attention/executive functions independently of A β level. However, generalizability is limited given that this study was conducted in a racially/ethnically homogenous, clinic-based sample with few medical comorbidities. Replication of these findings in a more representative sample will better inform the range of pathologic and associated cognitive changes in AD. Additionally, extending analyses to other regions of tau deposition and other pathologies such as TDP-43 and cerebrovascular changes will provide more insight into the polypathologic nature of AD and the widespread influence of APOE genotypic variations on disease expression.

Our findings suggest that APOE may exert deleterious effects on cognition through specific interactions with tau pathology and that these effects may occur independently of and prior to the amyloidosis of AD. This relationship has important implications for models of AD pathogenesis by supporting an A β -independent role of APOE and tau during the preclinical period of AD that is further amplified in the presence of high A β .

Acknowledgments

This work was supported by NSF fellowship DGE-1650112 (A.J.W.) and NIH grants R01 AG049810 and R01 AG054049 (M.W.B.). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Author Contributions

AJW: conception and design of the study, acquisition and analysis of data, drafting manuscript and/or figures

KRT: conception and design of the study, revising the manuscript for intellectual content

KJB: conception and design of the study, revising the manuscript for intellectual content

GMLE: conception and design of the study, revising the manuscript for intellectual content

LDW: conception and design of the study, revising the manuscript for intellectual content

PEG: conception and design of the study, revising the manuscript for intellectual content

AMB: conception and design of the study, revising the manuscript for intellectual content

MWB: conception and design of the study, acquisition and analysis of data, revising the manuscript for intellectual content

Potential Conflicts of Interest

Ms. Weigand, Dr. Bangen, Dr. Thomas, Dr. Eglit, Dr. Delano-Wood, Dr. Gilbert, and Dr. Brickman report no competing interests. Dr. Bondi receives royalties from Oxford University Press and serves as a consultant for Eisai, Novartis and Roche Pharmaceutical companies.

References

- 1.) Hardy, J. The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis.” *The FEBS Journal*. 2017;284(7):1040-1044.
doi:10.1111/febs.14004
- 2.) Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol*. 2010;9(1):119–128.
doi:10.1016/S1474-4422(09)70299-6
- 3.) Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535–562.
doi:10.1016/j.jalz.2018.02.018
- 4.) Corders EH, Saunders EM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families. *Science*. 1993;261(5123):921–923.
- 5.) Hersi M, Irvine B, Gupta P, Gomes J, Birkett N, Krewski D. Risk factors associated with the onset and progression of Alzheimer’s disease: A systematic review of the evidence. *Neurotoxicology*. 2017;61:143–187.
- 6.) Kanekiyo T, Xu H, Bu G. ApoE and A β in Alzheimer's disease: accidental encounters or partners?. *Neuron*. 2014;81(4):740–754. doi:10.1016/j.neuron.2014.01.045
- 7.) Zhao N, Liu CC, Qiao W, Bu G. Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. *Biol Psychiatry*. 2018;83(4):347–357. doi:10.1016/j.biopsych.2017.03.003

- 8.) Lim YY, Mormino EC; Alzheimer's Disease Neuroimaging Initiative. *APOE* genotype and early β -amyloid accumulation in older adults without dementia. *Neurology*. 2017;89(10):1028–1034. doi:10.1212/WNL.0000000000004336
- 9.) Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. *JAMA*. 2015;313(19):1939–1949. doi:10.1001/jama.2015.4669
- 10.) Braak H & Del Tredici K. When, where, and in what form does sporadic Alzheimer's disease begin? *Curr Opin Neurol*. 2012;25(6):708-714.
- 11.) Ehrenberg AJ, Nguy AK, Theofilas P, et al. Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease. *Neuropathol Appl Neurobiol*. 2017;43(5):393–408. doi:10.1111/nan.12387
- 12.) Younes L, Albert M, Moghekar A, Soldan A, Pettigrew C, Miller MI. Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease. *Front Aging Neurosci*. 2019;11:74. Published 2019 Apr 2. doi:10.3389/fnagi.2019.00074
- 13.) Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol*. 2014;128(6):755–766. doi:10.1007/s00401-014-1349-0
- 14.) Braak H & Del Tredici K. Are cases with tau pathology occurring in the absence of A β deposits part of the AD-related pathological process? *Acta Neuropathol*. 2014;128(6):767-772.

- 15.) Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology*. 2016;87(5):539–547.
doi:10.1212/WNL.0000000000002923
- 16.) Shi Y, Yamada K, Liddel SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature*. 2017;549(7673):523–527.
doi:10.1038/nature24016
- 17.) Wolf AB, Valla J, Bu G, et al. Apolipoprotein E as a β -amyloid-independent factor in Alzheimer's disease. *Alzheimers Res Ther*. 2013;5(5):38. doi:10.1186/alzrt204
- 18.) Landau S & Jagust W. Flortaucipir (AV-1451) processing methods. <http://adni.loni.usc.edu/>.
Published March 2, 2016.
- 19.) Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann Neurol*. 2012;72(4):578–586. doi:10.1002/ana.23650
- 20.) Landau S & Jagust W. Florbetapir processing methods. <http://adni.loni.usc.edu/>. Published
December 3, 2015.
- 21.) Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. *Neuroimage*. 2017;157:448–463.
doi:10.1016/j.neuroimage.2017.05.058
- 22.) Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. *Data Brief*. 2017;15:648–657. doi:10.1016/j.dib.2017.10.024
- 23.) Jack CR Jr, Wiste HJ, Therneau TM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. *JAMA*. 2019;321(23):2316–2325. doi:10.1001/jama.2019.7437

- 24.) Mishra S, Gordon BA, Su Y, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. *Neuroimage*. 2017;161:171–178.
doi:10.1016/j.neuroimage.2017.07.050
- 25.) Wang L, Benzinger TL, Su Y, et al. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β -Amyloid and Tauopathy. *JAMA Neurol*. 2016;73(9):1070–1077. doi:10.1001/jamaneurol.2016.2078
- 26.) Schöll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging Human Brain. *Neuron*. 2016;89(5):971–982. doi:10.1016/j.neuron.2016.01.028
- 27.) Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. *J Nucl Med*. 2012;53(3):378-384. doi: 10.2967/jnumed.111.090340
- 28.) Bondi MW, Edmonds EC, Jak AJ, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis*. 2014;42(1):275–289. doi:10.3233/JAD-140276
- 29.) Jak AJ, Bondi MW, Delano-Wood L, et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. *Am J Geriatr Psychiatry*. 2009;17(5):368–375. doi:10.1097/JGP.0b013e31819431d5
- 30.) Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):280–292. doi:10.1016/j.jalz.2011.03.003

- 31.) Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology*. 2016;87(5):539–547.
doi:10.1212/WNL.0000000000002923
- 32.) Braak H, Thal DR, Ghebremedhin E, & Del Tredici K. Stages of the pathologic process in Alzheimer's disease: age categories from 1-100 years. *Journal of Neuropathology and Experimental Neurology*. 2011;70(11):960-969. doi:10.1097/NEN.0b013e318232a379
- 33.) Duckyaerts C, Braak H, Brion JP, et al. PART is part of Alzheimer disease. *Acta Neuropathol*. 2015;129(5):749–756. doi:10.1007/s00401-015-1390-7
- 34.) Brier MR, Gordon B, Friedrichsen K, et al. Tau and A β imaging, CSF measures, and cognition in Alzheimer's disease. *Sci Transl Med*. 2016;8(338):338ra66.
doi:10.1126/scitranslmed.aaf2362
- 35.) Hanseeuw BJ, Betensky RA, Jacobs HL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study [published online ahead of print, 2019 Jun 3] [published correction appears in JAMA Neurol. doi: 10.1001/jamaneurol.2019.2144]. *JAMA Neurol*. 2019;76(8):915–924.
doi:10.1001/jamaneurol.2019.1424
- 36.) Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. *Brain*. 2016;139(Pt 5):1551–1567.
doi:10.1093/brain/aww027
- 37.) Liao F, Yoon H, Kim J. Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. *Curr Opin Lipidol*. 2017;28(1):60–67.
doi:10.1097/MOL.0000000000000383

38.) Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. *Sci Transl Med*. 2011;3(89):89ra57.

doi:10.1126/scitranslmed.3002156

39.) Verghese PB, Castellano JM, Garai K, et al. ApoE influences amyloid- β (A β) clearance despite minimal apoE/A β association in physiological conditions. *Proc Natl Acad Sci U S A*. 2013;110(19):E1807–E1816. doi:10.1073/pnas.1220484110

40.) Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kaye R. Preparation and characterization of neurotoxic tau oligomers. *Biochemistry*.

2010;49(47):10039–10041. doi: 10.1021/bi1016233

41.) Nilson AN, English KC, Gerson JE, et al. Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. *J Alzheimers Dis*. 2017;55(3):1083–1099. doi:10.3233/JAD-160912

42.) F   M, Puzzo D, Piacentini R, et al. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. *Sci Rep*. 2016;6:19393. Published 2016 Jan 20. doi:10.1038/srep19393

43.) Piacentini R, Li Puma DD, Mainardi M, et al. Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. *Glia*. 2017;65(8):1302–1316. doi:10.1002/glia.23163

	ε4 carriers (n=99)	Non-carriers (n=198)	Test statistic	p-value
Age (Mean[SE])	74.28(.72)	76.50(.52)	t = 2.50	p = .01
Sex (% female)	53.5 % female	46.5% female	$\chi^2 = 1.05$	p = .30
Education (Mean[SE])	16.51(.27)	16.83(.17)	t = 1.05	p = .29
Aβ status (% A+)	50.5% A+	23.7% A+	$\chi^2 = 20.30$	p < .001
Tau status (% T+)	72.7% T+	71.7% T+	$\chi^2 = .002$	p = .96
Cortical amyloid SUVR (Mean[SE])	1.21(.02)	1.09(.01)	t = 5.07	p < .001
MTL tau SUVR (Mean[SE])	1.39(.03)	1.32(.02)	t = 2.13	p = .03
Attention/executive (Mean[SE])	-.45(.13)	-.25(.08)	t = 1.37	p = .17
Language (Mean[SE])	-.46(.14)	-.38(.09)	t = .49	p = .62
Memory (Mean[SE])	-.65(.14)	-.43(.08)	t = 1.41	p = .16

Table 1. APOE ε4-carrier and non-carrier group differences in demographic and PET variables.

Figure Legends

Figure 1. Quadratic moderating effect of $\epsilon 4$ -carrier status on the association between medial temporal lobe tau and memory performance.

Figure 2. A: Quadratic moderating effect of $\epsilon 4$ -carrier status on the association between medial temporal lobe tau and memory performance among amyloid beta negative individuals. B: Linear moderating effect of $\epsilon 4$ -carrier status on the association between medial temporal lobe tau and memory performance among amyloid beta positive individuals.



